Medications
Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)
10/23/2018
MALVERN, Penn. — October 15, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to
Read More